论文部分内容阅读
目的 探讨肝癌患者血清血管内皮生长因子 (vascularendothelialgrowthfactor,VEGF)表达情况及临床意义。方法 选择 70例肝癌、30例肝硬化和 2 0例正常对照血清标本 ,采用定量ELISA法检测血清VEGF含量。记录肝癌组临床病理特征 ,与肝癌组血清VEGF水平做相关性分析。结果 肝癌组血清VEGF显著高于肝硬化组和正常对照组 (P <0 0 5 ,P <0 0 0 1)。肝癌患者血清VEGF与肿块大小成正相关 (P <0 0 5 ) ;出现液化坏死病变、伴有远处转移 ,及肝癌切除术后复发患者血清VEGF水平明显增高 (P <0 0 5 ) ,TNMⅢ、Ⅳ期患者血清VEGF浓度也明显高于TNMⅠ、Ⅱ期患者 (P <0 0 5 )。结论 血清VEGF水平可作为肝癌诊断和预后评价的重要指标
Objective To investigate the expression of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma and its clinical significance. Methods Seventy patients with HCC, 30 cirrhosis and 20 normal controls were enrolled in this study. Serum VEGF levels were measured by quantitative ELISA. The clinicopathological features of HCC were recorded, and the correlation with serum VEGF level was analyzed. Results The serum level of VEGF in HCC group was significantly higher than that in cirrhosis group and normal control group (P <0.05, P <0.01). There was a positive correlation between serum VEGF and tumor size in patients with liver cancer (P <0.05). Serum levels of VEGF in patients with liquefied necrosis, distant metastasis and recurrence after hepatectomy were significantly higher (P <0.05) Serum VEGF levels in patients with stage IV were also significantly higher than those in patients with stage TNM I and II (P <0.05). Conclusion Serum VEGF levels can be used as an important indicator of diagnosis and prognosis of liver cancer